Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeDDiS phase III trial of gemcitabine + docetaxel versus doxorubicin in first-line advanced soft tissue sarcoma
2009-014907-29Phase 3Completed
- Sponsor
- University College London
- Start
- Jul 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS) comparing Gemcitabine + docetaxel with Doxorubicin (2 arms). Primary endpoint: Proportion of patients alive and progression free at 24 weeks after randomisation. Started Jul 2010; status: completed.
02
Drugs
gemcitabinedocetaxeldoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2009-014907-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014907-29.